- Meta must limit data use for targeted ads: EU court
- Oil extends gains, jobs report lifts Wall Street
- US hiring soars past expectations in sign of resilient market
- As EU targets Chinese cars, European rivals sputter
- Top EU court finds against FIFA in key transfer market ruling
- Oil extends gains, Hong Kong stocks resume rally
- 'A man provides': Ukrainian miners send families away as Russia advances
- EU states greenlight extra tariffs on EVs from China
- Hong Kong stocks resume rally, oil dips after Middle East-fuelled surge
- Crude stable after Israel-Iran surge, Hong Kong stocks resume gains
- Hera spacecraft to probe asteroid deflected by defence test
- US dockworkers to head back to work after tentative deal
- After Helene's destruction, North Carolina starts to rebuild
- Dockers end three-day strike at Montreal port
- What next for OpenAI after $157 billion bonanza?
- Israel-Hamas war causes 86-percent dive in Gaza GDP: IMF
- Milan's Morata moves house after Inter-fan town mayor 'violates' privacy
- 'Devastating' storm hits Augusta National but Masters will go on
- Relief in Brazil, Asia over delay to EU deforestation rules
- Oil prices jump, stocks fall on Middle East tensions
- Biden says 'discussing' possible Israeli strikes on Iran oil facilities
- Oil prices rise, stocks fall on Middle East tensions
- Oil rallies, stocks mostly retreat on Middle East tensions
- Phasing out teen smoking could save 1.2 mn lives: study
- 'Welcome relief': Asia producers hail EU deforestation law delay
- Japan PM slated to announce plans for 'happiness index'
- Turkish inflation falls less than expected in September at 49.4%
- Easing inflation lifts profit at UK supermarket Tesco
- Skiing calls on UN climate science to combat melting future
- China wine industry looks to breed climate resilience
- Tokyo rallies on weak yen, Hong Kong drops after surge
- Dutch airline KLM unveils 'firm' cost-cutting measures
- Carpe diem: the Costa Rican women turning fish into fashion
- Senegal looks to aquaculture as fish stocks dwindle
- Will AI one day win a Nobel Prize?
- Climate change, economics muddy West's drive to curb Chinese EVs
- Argentina's Milei vetoes university budget after huge protests
- TotalEnergies plans to grow oil and gas production until 2030
- 2024 Nobels offer glimmer of hope as global crises mount
- Tokyo rallies on weak yen, Hong Kong reverses after surge
- Tunisia readies for vote as incumbent Saied eyes victory
- High childcare costs in US weigh on women's employment
- US voters seek help with crushing childcare costs
- Taiwan shuts down for second day as Typhoon Krathon to land
- Supercharged storms: how climate change amplifies cyclones
- Biden official urges talks as US port strike enters second day
- Huge protests in Argentina over public university cuts
- Rally in oil prices loses steam on mixed day for global stocks
- South America treated to rare 'ring of fire' eclipse
- Biden official says port strike deal not as far as parties think
RBGPF | -3.17% | 58.93 | $ | |
RYCEF | 0% | 6.98 | $ | |
BCC | -1.26% | 136.57 | $ | |
CMSC | -0.2% | 24.69 | $ | |
NGG | -1.16% | 66.205 | $ | |
RIO | -0.68% | 69.36 | $ | |
GSK | 0.07% | 38.395 | $ | |
RELX | -1.51% | 45.915 | $ | |
CMSD | -0.22% | 24.835 | $ | |
JRI | -0.04% | 13.295 | $ | |
SCS | 1.41% | 12.8 | $ | |
BTI | -0.06% | 35.09 | $ | |
BCE | -0.15% | 33.79 | $ | |
VOD | -0.21% | 9.67 | $ | |
AZN | -1.16% | 77.035 | $ | |
BP | 0.98% | 32.78 | $ |
Pfizer in talks on $5 billion acquisition: media
American drugmaker Pfizer is close to a deal to purchase Global Blood Therapeutics, which manufactures a recently approved drug against sickle-cell anemia, for $5 billion, the Wall Street Journal has reported.
Pfizer, one of the top makers of Covid-19 vaccines, hopes to conclude talks with GBT within days, the newspaper said Friday, citing people close to the negotiations.
But it said other takeover candidates remain in the running.
GBT's sickle-cell treatment, marketed as Oxbryta, was authorized for those over 12 years old in 2019 but gained federal approval in December for children aged four to 11. The blood disorder affects millions.
Sales of Oxbryta helped the laboratory generate first-quarter turnover of $55 million (up 41 percent), while the company registered a net loss of $81.4 million.
GBT, which is based in San Francisco, California, is to publish its second-quarter numbers on Monday.
Pfizer, for its part, saw its second-quarter turnover jump by 47 percent -- to a record $27.74 billion -- boosted by sales of its Covid vaccine and pills.
Its net profit soared by 78 percent, to $9.9 billion.
GBT shares on the New York Stock Exchange were up 33.03 percent at the close on Friday, at $63.84, for a market capitalization of more than $4 billion.
Pfizer shares slipped by 1.18 percent, to $49.27.
Y.Ibrahim--CPN